BELLBERRY LIMITED RELEASES CLINICAL TRIAL ACTIVITY REPORT 2024 Nation’s largest reviewer of clinical trials across Australia through Human Research Ethics Committees (HRECs)
With
Kylie Sproston, Chief Executive Officer
Bellberry Limited, Adelaide
AUSTRALIAN HEALTH JOURNAL SEGMENT
Filmed in Adelaide | May 2025
Released in the week of International Clinical Trials Day 2025
Established in 2004, Bellberry is a Adelaide-based national, not-for-profit organisation that provides streamlined scientific and ethical reviews of human research. It is the 2025 winner of the Championing Health Award in the Telstra Best of Business Awards.
Australian Health Journal spoke with Bellberry Limited CEO, Kylie Sproston on the organisation and the findings in activity documented in the Clinical Trial Activity Report (CTAR) 2024.
Global investment in Australian clinical trials is strong, with two thirds of Australian clinical trials, reviewed by Bellberry, funded by international companies according to the CTAR.
Bellberry is Australia’s largest ethics and scientific reviewer of research involving humans reviewing approximately 40% of CTN (Clinical Trial Notification) trials in Australia.
Every year since 2019, Bellberry has released its Clinical Trial Activity Report (CTAR) to coincide with International Clinical Trials Day on 20 May. The CTAR describes the portfolio of research conducted in the prior year with Bellberry oversight.
Bellberry CEO, Kylie Sproston, says the 2024 data shows that Australia is uniquely placed to attract worldwide investment in clinical trials activity due to the high quality of its healthcare institutions and researchers.
“The 2024 Clinical Trial Activity Report shows that early phase trial activity remains a key strength with significant and continued growth over the last six years,” said Ms Sproston.
“The USA is the largest driver of early phase trials conducted in Australia, with Australia coming second and China third. Other top 10 countries include Germany, South Korea, Switzerland, the UK, Canada, France and Japan,” she said.
“Almost 50 per cent of the trials that Bellberry reviews are First in Human or Phase 1 trials, highlighting Australia’s strong reputation for this skilled and complex type of research.”
In 2024, oncology accounted for more than a quarter of the studies reviewed by Bellberry, while non-clinical trials made up more than 15 per cent of Bellberry reviews.
“Interestingly, we have seen a doubling of the number of social science research activities that Bellberry has reviewed in the last six years from 5% to 10% of total reviews,” said Ms Sproston.
“Australia’s capacity to support the full clinical development pathway is highlighted by the representation of trials in the 2024 CTAR from FIH through to Phase 4, devices, observational, qualitative, social science, registry, audit, and evaluation.”
The CTAR can be downloaded from the Bellberry Limited website.
Source: Adapted from Bellberry Limited News Story
-
Updated handbook on chronic kidney disease management in primary care
Kidney Health Australia’s latest kidney disease guide for primary care practitioners is expected to be pivotal in slowing down the rates of kidney failure, which have doubled in the past 20 years and if left unchecked will grow by a further 42% by 2030, according to the health charity.
With specific reference to new kidney treatments and culturally safe kidney care for First Nations Australians, the 5th edition of Chronic Kidney Disease (CKD) Management in Primary Care handbook, known as the ‘kidney bible’, is a significant step-up in enabling earlier diagnosis of kidney disease for GPs and other front-line healthcare professionals.
-
The desire for primary care nurses to do more, be recognised and valued for the work they do
Denise Lyons is a highly experienced nurse with over 40 years in the profession, including more than 25 years dedicated to primary care. She earned her Bachelor of Science in Nursing in the United States in 1985 and, in 2012, became an endorsed Nurse Practitioner in Australia. Currently, she serves as a primary care Nurse Practitioner in General Practice in Newcastle, where she is committed to delivering high-quality, patient-centred care that improves the health and wellbeing of her community.
-
Interventional radiologists offer alternative to hysterectomy
In Australia in the last five years, an estimated 6066 women per year have undergone hysterectomies to treat fibroid-related diseases, while just 145 women each year have undergone a uterine artery embolisation, or UAE.
The procedure can effectively treat the majority of bleeding uterine fibroids. Each year, thousands of Australian women undergo invasive and life-altering hysterectomies to treat debilitating pain and blood loss caused by uterine fibroids. But there’s another option: a minimally invasive, pin-hole procedure that treats the symptoms, yet leaves the uterus intact.
